// App-Quantinova.ai

e15227 : Efficacy and hepatotoxicity of Infliximab in resolving steroid-refractory immune-related adverse events (irAEs) in a real-world setting.

Researchers

Presenter

  • Thiago Pimentel Muniz

Principal Investigators

  • Daniel Vilarim Araujo

  • Anjie Yang

  • Hadas Sorotsky

  • Sareh Keshavarzi

  • Marcus O. Butler

  • Samuel Saibil

  • Anna Spreafico

  • David Hogg

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Department of Medical Imaging, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Institute of Oncology, Chaim Sheba Medical Center at Tel-Hashomer, Ramant Gan,...

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

Drug/Treatment

  • Infliximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved